Jacquelyne Gaddy, MD, MSc, MSCR

Siddique S, Wang R, Gaddy J, Stempel J, Warren J, Gross C, Ma X. Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic. Journal Of General Internal Medicine 2024, 1-9. PMID: 39495455, DOI: 10.1007/s11606-024-09153-3.

Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.

Sanoff H, Deal A, Patel J, Sorah J, Gaddy J, O’Neil B, Turk A, Irvin W, Boles J, Lee M, McRee A, Wardell A, Weck K, Basch E, Wood W, Innocenti F. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The Oncologist 2024, 29: 786-793. PMID: 38837045, PMCID: PMC11379652, DOI: 10.1093/oncolo/oyae122.

Gaddy J, Li G, Keller-Evans R, Bray D, MILLS J, Oberstein P, Kunz P, Sivakumar S. Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC). Journal Of Clinical Oncology 2024, 42: 4138-4138. DOI: 10.1200/jco.2024.42.16_suppl.4138.

Siddique A, Wang R, Gaddy J, Gross C, Ma X. Abstract C129: Impact of COVID-19 on colorectal cancer screening disparities: Results from a large commercially insured population in the United States. Cancer Epidemiology Biomarkers & Prevention 2023, 32: c129-c129. DOI: 10.1158/1538-7755.disp23-c129.

Reeder‐Hayes K, Jackson B, Baggett C, Kuo T, Gaddy J, LeBlanc M, Bell E, Green L, Wheeler S. Race, geography, and risk of breast cancer treatment delays: A population‐based study 2004–2015. Cancer 2023, 129: 925-933. PMID: 36683417, PMCID: PMC11578059, DOI: 10.1002/cncr.34573.

Nyrop K, Gaddy J, Charlot M. Obesity, Cancer, and Health Equity. American Journal Of Preventive Medicine 2023, 64: 595-598. PMID: 36610923, DOI: 10.1016/j.amepre.2022.10.024.

Stein J, Gaddy J, Sorah J, Wooten M, Gibson K, Collichio F. Seeking Racial Equity in Hematology and Oncology: a Fellow-Led Educational Series to Promote Reflection and Action. Journal Of Cancer Education 2023, 38: 1241-1244. PMID: 36598746, PMCID: PMC10463164, DOI: 10.1007/s13187-022-02255-8.

Gaddy JJ, Gross CP. Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment. JAMA Oncology 2022, 8: 1792-1793. PMID: 36301581, DOI: 10.1001/jamaoncol.2022.5006.

Gaddy J, Teal R, Bell E, Wheeler S, Reeder-Hayes K. Evaluation of facilitators and barriers of timely breast cancer care in North Carolina (NC): A qualitative study. Journal Of Clinical Oncology 2022, 40: 134-134. DOI: 10.1200/jco.2022.40.28_suppl.134.

Stein J, Gaddy J, Sorah J, Wooten M, Gibson K, Collichio F. Seeking racial equity in hematology and oncology: A fellow-led educational series to promote reflection and action. Journal Of Clinical Oncology 2022, 40: 11004-11004. DOI: 10.1200/jco.2022.40.16_suppl.11004.

Gaddy J, Sanoff H, Deal A, Basch E, Wood W. Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. Journal Of Clinical Oncology 2022, 40: 51-51. DOI: 10.1200/jco.2022.40.4_suppl.051.

Reeder-Hayes K, Baggett C, Jackson B, Kuo T, Gaddy J, Bell E, Green L, Wheeler S. Racial differences in impact of geography on breast cancer treatment delay. Journal Of Clinical Oncology 2021, 39: 81-81. DOI: 10.1200/jco.2020.39.28_suppl.81.

Marron J, Charlot M, Gaddy J, Rosenberg A. The Ethical Imperative of Equity in Oncology: Lessons Learned From 2020 and a Path Forward. American Society Of Clinical Oncology Educational Book 2021, 41: e13-e19. PMID: 34061560, DOI: 10.1200/edbk_100029.

Moses K, Orom H, Brasel A, Gaddy J, Underwood W. Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter? Urology 2016, 99: 76-83. PMID: 27667157, PMCID: PMC5191943, DOI: 10.1016/j.urology.2016.07.045.

Moses K, Orom H, Brasel A, Gaddy J, Underwood W. Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer. Urologic Oncology Seminars And Original Investigations 2016, 34: 415.e7-415.e12. PMID: 27161898, PMCID: PMC4996674, DOI: 10.1016/j.urolonc.2016.04.002.

Moses K, Orom H, Brasel A, Gaddy J, Underwood W. MP5-15 EMERGING DISPARITY IN TREATMENT FOR PROSTATE CANCER AMONG HISPANIC MEN- DATA FROM SEER 2004–2009. Journal Of Urology 2015, 193: e50-e51. DOI: 10.1016/j.juro.2015.02.242.

Ghoshal P, Chitta K, Vujcic S, Gaddy J, Miles K, Stein L, Sher T, Lee K, Chanan-Khan A. Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma. Blood 2009, 114: 2832. DOI: 10.1182/blood.v114.22.2832.2832.